Please assess the completion status of the following clinical trial:

Trial Title: Shifting Pain Modulation From Pro-to Anti-nociceptive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* American society of anesthesiologists (ASA) I - III patients planned for elective herniorraphy.~Exclusion Criteria:~* Report of pain at hernia site for more than 30 on 0-100 Numeric Pain Scale (NPS) (ranging from 0, denoting ''no pain'', to 100, denoting ''the worst pain imaginable''), for most of the days during past one month.~* Regular use of analgesia for any purpose, including serotonin-norepinephrine re-uptake inhibitors (SNRIs) and gabapentins during the previous month.~* Use of monoamine oxidase inhibitors (MAOIs) within the last 14 days.~* Narrow-angle glaucoma.~* Known pregnancy or lactation.~* Chronic pain disorders.~* Inability to perform psycho-physical testing, as in the case of cognitive or psychiatric disorders. Participants will sign a consent form before recruitment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Duloxetine (Type: ACTIVE_COMPARATOR): Treatment
- Pregabalin (Type: ACTIVE_COMPARATOR): Treatment
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).